Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Poultry Science|December 6, 2025
Dietary calcium, non-phytate phosphorus, and electrolyte balance in low-protein diets for laying hens: Evaluating laying performance, egg quality, and nutrient utilizationXinyi Zhang, Jiayi Shi, Qingyuan Li, et al.
The Journal of Dermatological Treatment|August 12, 2017
Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trialApril Armstrong, Luis Puig, Richard Langley, et al.
American Journal of Clinical Dermatology|November 13, 2018
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 StudiesApril W Armstrong, Kristian Reich, Peter Foley, et al.
Annals of the Rheumatic Diseases|November 13, 2014
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE studyAtul Deodhar, Jürgen Braun, Robert D Inman, et al.
The Journal of Dermatological Treatment|July 15, 2020
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1Christopher E M Griffiths, Kim A Papp, Michael Song, et al.
The Journal of Rheumatology|April 17, 2014
The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trialDésirée van der Heijde, Atul Deodhar, Jürgen Braun, et al.
The Journal of Rheumatology|May 3, 2014
The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trialClifton O Bingham, Michael Weinblatt, Chenglong Han, et al.
American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.
Arthritis and Rheumatism|July 29, 2006
Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trialDésirée van der Heijde, Chenglong Han, Kirt DeVlam, et al.
Arthritis Care & Research|May 14, 2013
Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trialArthur Kavanaugh, Iain B McInnes, Gerald G Krueger, et al.
Pageof 9